Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the generative design of small molecules for the pharmaceuti...
Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform huma...
TaiMed Biologics (TPEX: 4147) announced that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) ha...
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapie...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with...
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas Insilico Medicine ("Insilico" HKEX:3696), a ...
Further expansion of the existing strategic partnership reflects continued high demand for Lonza’s high-quality global biologics outsourcing de...
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality...
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults wit...
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of He...
First and only CDK4/6 inhibitor approved for HR+ metastatic disease regardless of HER2 status Approval based on data from the collaborative Phase 3 ...
First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch ex...
© 2026 Biopharma Boardroom. All Rights Reserved.
